BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
infigratinib: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 1 upcoming FDA event(s), 0 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: QED Therapeutics, a BridgeBio company, BridgeBio Pharma, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2028-01-01 (half) | PDUFA date (company-disclosed) | pending | BridgeBio Pharma, Inc. BBIO | infigratinib | PDUFA first half of 2028 - BridgeBio Pharma, Inc. (infigratinib) |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P2/P3 | QED Therapeutics, a BridgeBio company | NCT06873035 An Interventional Study of Infigratinib in Children With Hypochondroplasia | Hypochondroplasia | enrolling by invitation | 24 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| None in the last 180 days. | ||||||
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.